Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Last trade$8.61
Day change+$0.305 (+3.67%)
Day range$8.07 – $8.98
Volume3,332,711
Market cap$483M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$482.58M
Price / earnings
—
Price / book
2.3×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.9×
Profitability
Earnings per share
-$2.54
Return on assets
-44.65%
Return on equity
-70.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.77×
Quick ratio
6.77×
Cash ratio
1.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$145.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CAPR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$11.13M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$11.13M
Selling, general and administrative
$15.12M
$14.08M
$9.4M
$6.02M
$5.92M
$5.67M
$6.07M
$4.27M
Research and development
$29.56M
$28.87M
$27.38M
$23.13M
$20.36M
$22.05M
$18.92M
$14.55M
Total operating expenses
$44.68M
$42.95M
$36.77M
$29.16M
$26.28M
$27.72M
$24.98M
$18.83M
Operating income
-$44.68M
-$42.95M
-$36.77M
-$29.16M
-$26.28M
-$27.72M
-$24.98M
-$7.7M
Interest expense
$0
$0
$0
-$3.05M
$0
$0
$0
$0
Income before taxes
-$42.66M
-$40.73M
-$33.94M
-$30.17M
-$24.57M
-$25.91M
-$24.39M
-$7.12M
Income taxes
$0
$1.6K
$0
$1.6K
$0
$1.6K
$0
$1.6K
Net income
-$42.66M
-$40.73M
-$33.94M
-$30.17M
-$24.57M
-$25.91M
-$24.39M
-$7.12M
Net income attributable to common shareholders
-$42.66M
-$40.73M
-$33.94M
-$30.17M
-$24.57M
-$25.91M
-$24.39M
-$7.12M
EBITDA
-$43.78M
-$42.38M
-$36.24M
-$28.65M
-$25.79M
-$27.23M
-$24.58M
-$7.32M
Basic earnings per share
-$0.73
-$0.70
-$0.59
-$0.62
-$0.54
-$0.57
-$0.53
-$0.16
Diluted earnings per share
-$0.73
-$0.70
-$0.59
-$0.62
-$0.54
-$0.57
-$0.53
-$0.16
Recent news
Company coverage with links to the original publishers.
Capricor Therapeutics announced that its HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The cardiac data showed that Deramiocel improved left ventricular ejection fraction by 2.8 percentage points in cardiomyopathy patients (p=0.02) and reduced new heart scarring by 2.9 segments compared to natural history controls (p=0.01). The company's Biologics License Application remains under FDA review with a PDUFA target action date of November 22, 2026.
Capricor Therapeutics faces a securities class action lawsuit alleging materially misleading statements regarding clinical trial data for its lead drug candidate deramiocel. The company's stock crashed 64% after FDA briefing documents revealed undisclosed modifications to the statistical analysis plan for the HOPE-3 study, which failed to meet pre-specified primary and secondary efficacy endpoints. Investors with losses between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.
Faruqi & Faruqi, LLP is investigating securities fraud claims against Capricor Therapeutics for allegedly making misleading statements about its Deramiocel drug's regulatory prospects. The company allegedly failed to disclose changes to its statistical analysis plan and lack of FDA agreement before resubmitting the Biologics License Application. Capricor's stock plummeted 64% on July 27, 2026, after the FDA released unfavorable briefing documents, and fell an additional 36% on July 30, 2026, following an AdCom panel's 9-3 vote against the drug's efficacy. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action lawsuit, with a September 28, 2026 deadline to seek lead plaintiff status.
Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics for making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.
A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan for clinical data without FDA approval before resubmitting its Biologics License Application, creating significant risk of regulatory rejection. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 are eligible to join the lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.